Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NKTR Nektar Therapeutics	$25.72 +9.0%	$20.41	$6.45 ▼ $37.38	$292.80M	0.95	689,624 shs	1.21 million shs
URGN Urogen Pharma	$20.11 +4.7%	$14.91	$3.42 ▼ $21.01	$888.27M	1.12	1.38 million shs	1.22 million shs
VERV Verve Therapeutics	$11.13	$10.34	$2.86 ▼ $11.40	$992.13M	2.23	3.94 million shs	N/A

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NKTR Nektar Therapeutics	+5.03%	+4.61%	-5.64%	+120.05%	+41.74%
URGN Urogen Pharma	+5.26%	-7.34%	+34.83%	+94.53%	+32.32%
VERV Verve Therapeutics	0.00%	0.00%	+0.91%	+158.24%	+138.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership
NKTR Nektar Therapeutics	4.2708 of 5 stars	3.4	3.0	4.2	3.4	2.5
URGN Urogen Pharma	4.6704 of 5 stars	4.5	4.0	4.5	2.2	2.5
VERV Verve Therapeutics	2.9193 of 5 stars	4.2	4.0	0.0	0.6	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	243.44% Upside
URGN Urogen Pharma	3.00	Buy	$31.43	56.28% Upside
VERV Verve Therapeutics	2.33	Hold	$14.57	30.92% Upside

Current Analyst Ratings Breakdown

Latest VERV, NKTR, and URGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
8/5/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/7/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NKTR Nektar Therapeutics	$98.43M	3.24	N/A	N/A	($1.95) per share	-13.19
URGN Urogen Pharma	$90.40M	10.29	N/A	N/A	($2.02) per share	-9.96
VERV Verve Therapeutics	$32.33M	30.69	N/A	N/A	$5.83 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NKTR Nektar Therapeutics	-$118.96M	-$8.80	N/A	N/A	N/A	-163.17%	-631.43%	-58.21%	N/A
URGN Urogen Pharma	-$126.87M	-$3.32	N/A	N/A	N/A	-164.44%	-97,487.15%	-59.38%	N/A
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest VERV, NKTR, and URGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	VERV Verve Therapeutics	-$0.70	N/A	N/A	N/A	$4.26 million	N/A
8/7/2025	Q2 2025	NKTR Nektar Therapeutics	-$3.13	-$2.95	+$0.18	-$2.95	$9.42 million	$11.18 million
8/7/2025	Q2 2025	URGN Urogen Pharma	-$0.82	-$1.05	-$0.23	-$1.05	$23.06 million	$24.22 million
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NKTR Nektar Therapeutics	N/A	2.61	3.24
URGN Urogen Pharma	N/A	4.14	3.99
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NKTR Nektar Therapeutics	75.88%
URGN Urogen Pharma	91.29%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
NKTR Nektar Therapeutics	5.25%
URGN Urogen Pharma	4.70%
VERV Verve Therapeutics	19.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NKTR Nektar Therapeutics	220	12.41 million	11.76 million	Optionable
URGN Urogen Pharma	200	46.26 million	44.09 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.94 million	Optionable

VERV, NKTR, and URGN Headlines

Recent News About These Companies

Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Thursday

August 13 at 2:50 AM | americanbankingnews.com

Canaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

August 9, 2025 | theglobeandmail.com

Verve Therapeutics Announces Merger and Nasdaq Delisting

August 3, 2025 | theglobeandmail.com

GSA Capital Partners LLP Buys 78,768 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

August 2, 2025 | marketbeat.com

Gene Therapy Companies Set Sights on Cardiovascular Disease

August 1, 2025 | genengnews.comG

Y Intercept Hong Kong Ltd Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

July 31, 2025 | marketbeat.com

Cwm LLC Purchases 24,841 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

July 30, 2025 | marketbeat.com

Cerity Partners LLC Invests $110,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)

July 30, 2025 | marketbeat.com

Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102

July 29, 2025 | msn.com

Eli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 26, 2025 | finanznachrichten.de

Verve Therapeutics (NASDAQ:VERV) Upgraded to "Hold" at Wall Street Zen

July 26, 2025 | marketbeat.com

Eli Lilly completes acquisition of Verve Therapeutics

July 25, 2025 | msn.com

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 25, 2025 | prnewswire.com

Lilly and Verve announce expiration of Verve tender offer

July 24, 2025 | prnewswire.com

Penn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli Lilly

July 24, 2025 | msn.com

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

July 24, 2025 | finance.yahoo.com

3 Bullish Biotech Stocks With Explosive Growth Trends

...

July 21, 2025 | marketbeat.com

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing

July 16, 2025 | thepharmaletter.comT

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)

...

July 15, 2025 | marketbeat.com

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

July 14, 2025 | msn.com

Biotech Stocks Are Ready to Rebound. 3 to Watch Now.

July 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VERV, NKTR, and URGN Company Descriptions

Nektar Therapeutics NASDAQ:NKTR

$25.72 +2.12 (+8.98%)

Closing price 04:00 PM Eastern

Extended Trading

$25.70 -0.02 (-0.10%)

As of 07:58 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Urogen Pharma NASDAQ:URGN

$20.11 +0.91 (+4.74%)

Closing price 04:00 PM Eastern

Extended Trading

$19.84 -0.27 (-1.32%)

As of 06:51 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Verve Therapeutics NASDAQ:VERV

$11.13 0.00 (0.00%)

As of 07/25/2025

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time